AUVELITY

Peak

dextromethorphan hydrobromide, bupropion hydrochloride

NDAORALTABLET, EXTENDED RELEASEPriority Review
Approved
Aug 2022
Lifecycle
Peak
Competitive Pressure
0/100

Mechanism of Action

(an ionotropic glutamate receptor) and a sigma-1 receptor agonist. The mechanism of dextromethorphan in the treatment of MDD is unclear. The mechanism of action of bupropion in the treatment of MDD is unclear; however, it may be related to noradrenergic and/or dopaminergic mechanisms. Bupropion…

Loss of Exclusivity

LOE Date
Apr 20, 2043
208 months away
Patent Expiry
Apr 20, 2043

Patent Records (5)

Patent #ExpiryTypeUse Code
8569328
Oct 29, 2033
Product
U-3419
10064857
Nov 5, 2034
U-3419
10080727
Nov 5, 2034
U-3419
10092560
Nov 5, 2034
U-3419
10092561
Nov 5, 2034
U-3419